KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Shares Outstanding: 2009-2024

Historic Shares Outstanding for Arbutus Biopharma (ABUS) over the last 9 years, with Dec 2024 value amounting to $190.0 million.

  • Arbutus Biopharma's Shares Outstanding rose 11.83% to $190.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $190.0 million, marking a year-over-year increase of 11.83%. This contributed to the annual value of $190.0 million for FY2024, which is 11.83% up from last year.
  • According to the latest figures from Q4 2024, Arbutus Biopharma's Shares Outstanding is $190.0 million, which was up 11.83% from $169.9 million recorded in Q4 2023.
  • In the past 5 years, Arbutus Biopharma's Shares Outstanding registered a high of $190.0 million during Q4 2024, and its lowest value of $69.0 million during Q1 2020.
  • Moreover, its 3-year median value for Shares Outstanding was $157.5 million (2022), whereas its average is $161.8 million.
  • Data for Arbutus Biopharma's Shares Outstanding shows a peak YoY soared of 61.67% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Shares Outstanding stood at $89.7 million in 2020, then spiked by 61.67% to $145.0 million in 2021, then grew by 8.60% to $157.5 million in 2022, then climbed by 7.88% to $169.9 million in 2023, then increased by 11.83% to $190.0 million in 2024.
  • Its last three reported values are $190.0 million in Q4 2024, $169.9 million for Q4 2023, and $165.1 million during Q1 2023.